« Back
Home /
Pioglitazone (hydrochloride)

Pioglitazone (hydrochloride)

Item no.	HY-14601-10mM
Manufacturer	MedChem Express
CASRN	112529-15-4
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 1 g 500 mg 5 g
Category	Metabolism Diabetes Glucose Homeostasis Cholesterol & Lipid Metabolism Regulation of Appetite Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.97
Citations	[1]Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve\|[2]Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84.\|[3]Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55.\|[4]Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. Inflammation. 2020 Apr;43(2):568-578.\|Int J Oncol. 2018 Aug;53(2):551-566.\|J Diabetes Res. 2019 Feb 3;2019:5245063.\|Mol Med Rep. 2024 Nov;30(5):209.\|Mol Med Rep. 2019 Jan;19(1):400-406.\|Acta Pharmacol Sin. 2021 Jan;42(1):160-170.\|Adv Sci (Weinh). 2024 Dec 25:e2407134.\|Adv Sci (Weinh). 2024 Oct 7:e2401931.\|Am J Physiol Heart Circ Physiol. 2021 Apr 9.\|Am J Physiol Renal Physiol. 2019 Jul 1;317(1):F137-F151.\|Biochem Eng J. 2021, 108104.\|BMC Complement Med Ther. 2022 Jul 1;22(1):176.\|Br J Pharmacol. 2021 Jun;178(11):2305-2323.\|Cancer Res. 2022 Apr 15;82(8):1503-1517.\|Cell Metab. 2021 Mar 2;33(3):581-597.e9.\|Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9.\|Food Chem Toxicol. 2021 Apr 6;112183.\|Gut Microbes. 2022, 14(1): 2139978.\|Heliyon. 2023 Apr 1.\|Immunology. 2023 Jan 28.\|Immunopharmacol Immunotoxicol. 2021 Aug 27;1-9.\|J Adv Res. 2024 Sep 29:S2090-1232(24)00427-2.\|J Ethnopharmacol. 2024 Nov 29:340:119128.\|J Steroid Biochem Mol Biol. 2023 Feb 1;229:106265.\|Med Sci Monit. 2019 Nov 13;25:8544-8553.\|Nutr Metab (Lond). 2019 Mar 5;16:17. \|Oxid Med Cell Longev. 2022.\|Res Sq. 2024 Jul 12.\|Research Square Preprint. 2021 Mar.\|SSRN. 2023 May 30.\|Tunku Abdul Rahman University. 2024 Mar 11.
Smiles	CCC1=CN=C(CCOC2=CC=C(CC3C(NC(S3)=O)=O)C=C2)C=C1.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	U 72107A,AD 4833
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	Ferroptosis; PPAR
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	392.90
Product Description	Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
Manufacturer - Research Area	Cancer; Metabolic Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)\|H2O: < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Isoform	PPARα; PPARβ/δ; PPARγ
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-14601-10mM-safety-datasheet.pdf